Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 12/20 | 0.54 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.53 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.53 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998475 | 0.85 | IL2 (0.50) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL5998577 | 0.83 | L3MBTL1 (0.46) | IL2STIM1ORAI1ORAI2L3MBTL1 | |
| SCHEMBL5999084 | 0.82 | IL2 (0.51) | IL2STIM1ORAI1ORAI2ALDH1A1 | |
| SCHEMBL5998369 | 0.80 | IL2 (0.45) | IL2STIM1ORAI1ORAI2KMT2A | |
| SCHEMBL1701180 | 0.77 | IL2 (0.51) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL15395777 | 0.76 | STIM1 (0.63) | IL2STIM1ORAI1ORAI2L3MBTL1 | |
| SCHEMBL15395892 | 0.76 | STIM1 (0.63) | IL2STIM1ORAI1ORAI2L3MBTL1 | |
| SCHEMBL11911928 | 0.75 | MEN1 (0.59) | IL2STIM1ORAI1ORAI2L3MBTL1 | |
| SCHEMBL15527973 | 0.75 | MEN1 (0.59) | IL2STIM1ORAI1ORAI2L3MBTL1 | |
| SCHEMBL5998235 | 0.75 | IL2 (0.44) | IL2STIM1ORAI1ORAI2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493427-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-1848435-B1 | COMPOUNDS AGAINST INFLAMMATIONS AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150266829-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | PRCL Research Inc. (CA) | 2015-09-24 | — | — | US | disclosed |
| US-8518950-B2 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20060173021-A1 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266829-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CCR9, CXCR2 | IL2 21/4885STIM1 2094/4885ORAI1 1129/4885 |
| US-20060173021-A1 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | TPMT, IL5, NAT1 | IL2 9/4885STIM1 2611/4885ORAI1 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.